MFN · company-page
MFN bolagssida och bolagsmetadata
17911 tecken · 1 HTML-del(ar)
Fulltext
MFN.se > AstraZeneca Pressmeddelanden Om oss Kontakt Privacy Policy Login Logga in med X Login Inställningar Split view Short keys for navigating in split view ↑ Select newer press release ↓ Select older press release ← Navigate backwards → Navigate forward Enter Navigate to line in focus Tab Focus next link A or 1 Open First attachment S or 2 Open Second attachment D or 3 Open Third attachment F or 4 Open Fourth attachment I Show company information PgUp Select newest press release PgDown Select oldest press release L Focus on filer bar N Increase preview window size M Decrease preview window size Esc Escape from mode Dark Mode Set dark mode to MFN.se Sound Plays a notification sound when new press release is published in the current feed Intresserad av platformen MFN för nyhetsdistribution? Läs mer Boka demo Logga in som bolag Onsdag 5 Augusti | 23:00:54 Europe / Stockholm Svenska | English AstraZeneca Kalender Est. tid* 2026-10-30 08:00 Kvartalsrapport 2026-Q3 2026-08-06 N/A X-dag halvårsutdelning AZN 79.500002 2026-07-27 - Kvartalsrapport 2026-Q2 2026-04-29 - Kvartalsrapport 2026-Q1 2026-04-09 - Årsstämma 2026-02-19 - X-dag halvårsutdelning AZN 159.500003 2026-02-10 - Bokslutskommuniké 2025 2025-11-06 - Kvartalsrapport 2025-Q3 2025-08-07 - X-dag halvårsutdelning AZN 76.700002 2025-07-29 - Kvartalsrapport 2025-Q2 2025-04-29 - Kvartalsrapport 2025-Q1 2025-04-11 - Årsstämma 2025-02-20 - X-dag halvårsutdelning AZN 167.999995 2025-02-06 - Bokslutskommuniké 2024 2024-11-12 - Kvartalsrapport 2024-Q3 2024-08-08 - X-dag halvårsutdelning AZN 77.600002 2024-07-25 - Kvartalsrapport 2024-Q2 2024-04-25 - Kvartalsrapport 2024-Q1 2024-04-11 - Årsstämma 2024-02-22 - X-dag halvårsutdelning AZN 155.999994 2024-02-08 - Bokslutskommuniké 2023 2023-11-09 - Kvartalsrapport 2023-Q3 2023-08-10 - X-dag halvårsutdelning AZN 71.799999 2023-07-28 - Kvartalsrapport 2023-Q2 2023-04-27 - Årsstämma 2023-04-27 - Kvartalsrapport 2023-Q1 2023-02-23 - X-dag halvårsutdelning AZN 162.800002 2023-02-09 - Bokslutskommuniké 2022 2022-11-10 - Kvartalsrapport 2022-Q3 2022-08-11 - X-dag halvårsutdelning AZN 76.4 2022-07-29 - Kvartalsrapport 2022-Q2 2022-04-29 - Årsstämma 2022-04-29 - Kvartalsrapport 2022-Q1 2022-02-24 - X-dag halvårsutdelning AZN 145.299995 2022-02-10 - Bokslutskommuniké 2021 2021-11-12 - Kvartalsrapport 2021-Q3 2021-08-12 - X-dag halvårsutdelning AZN 64.8 2021-07-29 - Kvartalsrapport 2021-Q2 2021-05-11 - Årsstämma 2021-04-30 - Kvartalsrapport 2021-Q1 2021-02-25 - X-dag halvårsutdelning AZN 137.399995 2021-02-11 - Bokslutskommuniké 2020 2020-11-05 - Kvartalsrapport 2020-Q3 2020-08-13 - X-dag halvårsutdelning AZN 69.599998 2020-07-30 - Kvartalsrapport 2020-Q2 2020-04-29 - Årsstämma 2020-04-29 - Kvartalsrapport 2020-Q1 2020-02-27 - X-dag halvårsutdelning AZN 146.399999 2020-02-14 - Bokslutskommuniké 2019 2019-10-24 - Kvartalsrapport 2019-Q3 2019-08-08 - X-dag halvårsutdelning AZN 71.899998 2019-07-25 - Kvartalsrapport 2019-Q2 2019-04-26 - Årsstämma 2019-04-26 - Kvartalsrapport 2019-Q1 2019-02-28 - X-dag halvårsutdelning AZN 146.800005 2019-02-14 - Bokslutskommuniké 2018 2018-11-08 - Kvartalsrapport 2018-Q3 2018-08-09 - X-dag halvårsutdelning AZN 68.400002 2018-07-26 - Kvartalsrapport 2018-Q2 2018-05-18 - Årsstämma 2018-05-18 - Kvartalsrapport 2018-Q1 2018-02-15 - X-dag halvårsutdelning AZN 133.599997 2018-02-02 - Bokslutskommuniké 2017 2017-11-09 - Kvartalsrapport 2017-Q3 2017-08-10 - X-dag halvårsutdelning AZN 68.900001 2017-07-27 - Kvartalsrapport 2017-Q2 2017-04-27 - Årsstämma 2017-04-27 - Kvartalsrapport 2017-Q1 2017-02-16 - X-dag halvårsutdelning AZN 150.199997 2017-02-02 - Bokslutskommuniké 2016 2016-11-10 - Kvartalsrapport 2016-Q3 2016-08-11 - X-dag halvårsutdelning AZN 68.699998 2016-07-28 - Kvartalsrapport 2016-Q2 2016-04-29 - Årsstämma 2016-04-29 - Kvartalsrapport 2016-Q1 2016-02-18 - X-dag halvårsutdelning AZN 145.555556 2016-02-04 - Bokslutskommuniké 2015 2015-11-05 - Kvartalsrapport 2015-Q3 2015-08-13 - X-dag halvårsutdelning AZN 63.88889 2015-07-30 - Kvartalsrapport 2015-Q2 2015-04-24 - Årsstämma 2015-04-24 - Kvartalsrapport 2015-Q1 2015-02-19 - X-dag halvårsutdelning AZN 138.888896 2015-02-05 - Bokslutskommuniké 2014 2014-11-06 - Kvartalsrapport 2014-Q3 2014-08-13 - X-dag halvårsutdelning AZN 59 2014-07-31 - Kvartalsrapport 2014-Q2 2014-04-24 - Årsstämma 2014-04-24 - Kvartalsrapport 2014-Q1 2014-02-19 - X-dag halvårsutdelning AZN 129.777777 2014-02-06 - Bokslutskommuniké 2013 2013-10-31 - Kvartalsrapport 2013-Q3 2013-08-14 - X-dag halvårsutdelning AZN 65.777779 2013-08-01 - Analytiker möte 2013 2013-08-01 - Kvartalsrapport 2013-Q2 2013-04-25 - Årsstämma 2013-04-25 - Kvartalsrapport 2013-Q1 2013-02-13 - X-dag halvårsutdelning AZN 133.888888 2013-01-31 - Bokslutskommuniké 2012 2012-10-25 - Analytiker möte 2012 2012-10-25 - Kvartalsrapport 2012-Q3 2012-08-08 - X-dag halvårsutdelning AZN 64.555556 2012-07-26 - Kvartalsrapport 2012-Q2 2012-04-26 - Årsstämma 2012-04-26 - Kvartalsrapport 2012-Q1 2012-02-15 - X-dag halvårsutdelning AZN 137.333333 2012-02-02 - Bokslutskommuniké 2011 2011-10-27 - Kvartalsrapport 2011-Q3 2011-08-03 - X-dag halvårsutdelning AZN 57.666665 2011-07-28 - Kvartalsrapport 2011-Q2 2011-04-28 - Årsstämma 2011-04-28 - Kvartalsrapport 2011-Q1 2011-02-02 - X-dag halvårsutdelning AZN 129.666662 2011-01-27 - Bokslutskommuniké 2010 2010-10-28 - Kvartalsrapport 2010-Q3 2010-08-04 - X-dag halvårsutdelning AZN 49.888888 2010-07-29 - Kvartalsrapport 2010-Q2 2010-04-29 - Kvartalsrapport 2010-Q1 2010-02-03 - X-dag halvårsutdelning AZN 117.111111 2010-01-28 - Bokslutskommuniké 2009 2009-10-29 - Kvartalsrapport 2009-Q3 2009-08-05 - X-dag halvårsutdelning AZN 40 2009-07-30 - Kvartalsrapport 2009-Q2 2009-04-30 - Årsstämma 2009-04-30 - Kvartalsrapport 2009-Q1 2009-02-04 - X-dag halvårsutdelning AZN 116.444444 2008-08-06 - X-dag halvårsutdelning AZN 30.888888 2008-02-06 - X-dag halvårsutdelning AZN 75.2222222 2007-08-08 - X-dag halvårsutdelning AZN 28.111111 2007-02-07 - X-dag halvårsutdelning AZN 70 2006-08-09 - X-dag halvårsutdelning AZN 32.562658 Beskrivning Land Storbritannien Lista FTSE 100 Sektor Hälsovård Industri Läkemedel & Handel AstraZeneca är ett globalt läkemedelsbolag med fokus på forskning, utveckling och marknadsföring av receptbelagda läkemedel, primärt för behandling av sjukdomar inom terapiområdena som berör andningsvägar, hjärta/kärl/metabolism och cancer. Utöver huvudverksamheten är bolaget även fokuserat på områdena autoimmunitet, neurovetenskap och infektion. AstraZeneca är verksamt inom samtliga globala regioner och har sitt huvudkontor i Cambridge, Storbritannien. Intresserad av bolagets nyckeltal? Analysera bolaget i Börsdata ! Vem äger bolaget? All ägardata du vill ha finns i Holdings ! Filter År Typ Språk Rensa Språk Använd filter Rensa Se endast PM som skrivits på följande språk Engelska Svenska Typ Använd filter Rensa Finansiella rapporter År Använd filter Rensa Se endast PM som skrivits från valt år 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 Språk Använd filter Rensa Se endast PM som skrivits på följande språk Engelska Svenska Typ Använd filter Rensa Finansiella rapporter 2026-07-31 08:35:35 AstraZeneca: Datroway[ ]approved in the EU as only TROP2-directed medicine with overall survival benefit for the 1st-line treatment of patients with metastatic TNBC who are not candidates for immunotherapy 12632,00 SEK | -0,69%  | 2 991 MSEK 2026-07-27 08:10:57 AstraZeneca: Update on Phase III trial of Ultomiris in adults and adolescents with thrombotic microangiopathy after haematopoietic stem cell transplant 4 135 MSEK 2026-07-27 08:06:42 AstraZeneca: Sonesitatug vedotin demonstrated a statistically significant and highly clinically meaningful improvement in overall survival in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers 4 135 MSEK 2026-07-27 08:00:30 Resultat för AstraZeneca: Första halvåret samt andra kvartalet 2026 4 135 MSEK 2026-07-27 08:00:00 AstraZeneca: Half-year Financial Report 4 135 MSEK 2026-07-24 13:09:02 AstraZeneca: Enhertu plus pertuzumab recommended for approval in the EU by CHMP as 1st-line treatment for patients with HER2-positive metastatic breast cancer 12670,00 SEK | -0,14%  | 2 990 MSEK 2026-07-24 12:45:13 AstraZeneca: Trixeo recommended for approval in the EU by CHMP for the maintenance treatment of asthma 12670,00 SEK | -0,14%  | 2 990 MSEK 2026-07-23 08:06:17 AstraZeneca: Etcamah (camizestrant) in combination with a CDK4/6 inhibitor approved in the EU for 1st-line advanced ER-positive breast cancer 12688,00 SEK | -0,11%  | 6 563 MSEK 2026-07-14 08:09:20 AstraZeneca enters exclusive global license agreement for novel oral EGFR inhibitor Zegfrovy for lung cancer with Dizal Pharmaceutical 12364,00 SEK | -1,95%  | 5 241 MSEK 2026-07-09 08:07:29 AstraZeneca: Update on CARDIO-TTRansform Phase III trial for Wainua (eplontersen) in adults with transthyretin-mediated amyloid cardiomyopathy 13354,00 SEK | -6,22%  | 12 627 MSEK 2026-06-29 08:49:21 Efzimfotase alfa showed bone health improvements in treatment-naïve paediatric patients with hypophosphatasia: median difference of 1.67 vs placebo in RGI-C Score at week 25 in MULBERRY Phase 3 trial 14298,00 SEK | -0,14%  | 3 494 MSEK 2026-06-29 08:38:42 AstraZeneca: Enhertu approved in the EU as first tumour agnostic HER2-directed therapy and antibody drug conjugate for patients with previously treated HER2-positive metastatic solid tumours 14298,00 SEK | -0,14%  | 3 494 MSEK 2026-06-26 13:15:45 AstraZeneca: Datroway[ ]recommended for approval in the EU by CHMP as 1st-line treatment for patients with metastatic triple-negative breast cancer who are not candidates for immunotherapy 14318,00 SEK | +1,82%  | 8 126 MSEK 2026-06-15 08:12:23 AstraZeneca: Ultomiris granted Priority Review in the US as treatment for adults with immunoglobulin A nephropathy 13200,00 SEK | -1,95%  | 3 058 MSEK 2026-06-15 08:07:47 AstraZeneca: Truqap combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer 13200,00 SEK | -1,95%  | 3 058 MSEK 2026-06-08 22:21:48 Elecoglipron, an oral small molecule GLP-1 RA, moves to Phase III programme and unlocks next chapter in AstraZeneca's cardiometabolic and kidney portfolio 13632,00 SEK | -1,19%  | 3 276 MSEK 2026-06-06 10:35:11 AstraZeneca: Ultomiris demonstrated 43.4% reduction in proteinuria vs placebo in adults with immunoglobulin A nephropathy at 34 weeks in I CAN Phase III trial 2026-06-02 14:06:40 AstraZeneca: Camizestrant combination delayed time to first progression by 55% and to second progression by 37% in patients with advanced HR-positive breast cancer with an emergent ESR1 mutation in SERENA-6 trial 13214,00 SEK | -1,64%  | 2 790 MSEK 2026-06-01 14:11:08 AstraZeneca: Imfinzi plus Imjudo combined with lenvatinib and TACE reduced the risk of disease progression or death by 30% in embolisation-eligible unresectable liver cancer in EMERALD-3 Phase III trial 13434,00 SEK | -2,67%  | 2 775 MSEK 2026-05-29 14:08:08 AstraZeneca: CARES Phase III clinical programme did not meet primary endpoint in overall AL amyloidosis population, however, demonstrated anselamimab as potential first anti-fibril therapy in kappa AL amyloidosis 13802,00 SEK | +0,48%  | 7 815 MSEK 2026-05-29 08:04:24 AstraZeneca: Imfinzi approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer 13802,00 SEK | +0,48%  | 7 815 MSEK 2026-05-27 08:04:50 AstraZeneca: US FDA decision date extended for SERENA-6 filing of camizestrant to enable review of additional data 14008,00 SEK | +0,34%  | 5 715 MSEK 2026-05-22 15:41:05 AstraZeneca: Datroway approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidates 13916,00 SEK | -0,64%  | 2 245 MSEK 2026-05-22 14:17:25 AstraZeneca: Enhertu recommended for approval in the EU by CHMP for patients with previously treated HER2-positive metastatic solid tumours 13916,00 SEK | -0,64%  | 2 245 MSEK 2026-05-22 13:24:28 AstraZeneca: Camizestrant in combination with a CDK4/6 inhibitor recommended for approval in the EU by CHMP for 1st-line advanced ER-positive breast cancer 13916,00 SEK | -0,64%  | 2 245 MSEK 2026-05-22 08:06:26 AstraZeneca to showcase Phase III data in liver, breast and bladder cancers and potential first-in-class rare disease therapy at ASCO 2026 13916,00 SEK | -0,64%  | 2 245 MSEK 2026-05-18 08:12:51 AstraZeneca: Enhertu approved in the US for two new indications for patients with HER2-positive early breast cancer 13710,00 SEK | +0,57%  | 2 417 MSEK 2026-05-18 08:07:19 AstraZeneca: Baxfendy approved in the US as the first and only aldosterone synthase inhibitor treatment for adults with hypertension 13710,00 SEK | +0,57%  | 2 417 MSEK 2026-05-14 08:05:47 AstraZeneca: Imfinzi + EV improves EFS & OS in bladder cancer 13740,00 SEK | -0,19%  | 1 211 MSEK 2026-05-12 13:06:57 AstraZeneca: Eneboparatide normalised serum calcium and achieved independence from active vitamin D and oral calcium supplements in 31.1% of adults with hypoparathyroidism at week 24 in CALYPSO Phase III trial 13748,00 SEK | +1,82%  | 5 510 MSEK 2026-05-04 08:18:52 AstraZeneca: Truqap recommended by FDA Advisory Committee for PTEN-deficient metastatic hormone-sensitive prostate cancer 2026-05-04 08:07:24 AstraZeneca: Update on FDA Advisory Committee vote on camizestrant in combination with a CDK4/6 inhibitor for advanced HR-positive breast cancer 2026-04-29 08:00:46 Resultat för AstraZeneca: Första kvartalet 2026 13692,00 SEK | -1,50%  | 4 139 MSEK 2026-04-28 08:06:53 AstraZeneca: Breztri approved in the US for asthma as first and only triple therapy for patients 12 years of age and older 13900,00 SEK | -0,52%  | 3 685 MSEK 2026-04-27 08:06:50 AstraZeneca: Saphnelo approved in the US for subcutaneous self-administration as a new autoinjector for the treatment of systemic lupus erythematosus 13972,00 SEK | +0,11%  | 3 761 MSEK 2026-04-23 08:42:53 Change to AstraZeneca Board of Directors 14492,00 SEK | -0,30%  | 4 920 MSEK 2026-04-21 08:06:50 AstraZeneca: Ultomiris demonstrated statistically significant and clinically meaningful reduction of proteinuria in adults with immunoglobulin A nephropathy in I CAN Phase III trial 14560,00 SEK | -2,62%  | 3 469 MSEK 2026-04-20 08:06:45 AstraZeneca: Tozorakimab met primary endpoint in Phase III MIRANDA trial in patients with COPD 14952,00 SEK | -1,10%  | 2 173 MSEK 2026-04-10 08:07:02 AstraZeneca: Alexion data at 2026 AAN Annual Meeting reflects industry-leading portfolio and commitment to enhancing care across rare diseases 15230,00 SEK | -0,30%  | 4 449 MSEK 2026-04-02 08:08:44 AstraZeneca: Imfinzi+Imjudo improves PFS in early liver cancer 15316,00 SEK | +1,96%  | 3 142 MSEK 2026-03-31 08:04:44 AstraZeneca: Efzimfotase alfa demonstrated positive results from global Phase III clinical programme in hypophosphatasia 14690,00 SEK | -0,08%  | 4 704 MSEK 2026-03-27 08:10:08 AstraZeneca: Tozorakimab met primary endpoint in both OBERON and TITANIA Phase III trials in patients with COPD 14302,00 SEK | +3,41%  | 4 784 MSEK 2026-03-16 08:07:26 AstraZeneca: Imfinzi approved in the EU as first and only perioperative immunotherapy for patients with early gastric and gastroesophageal cancers 14364,00 SEK | -0,11%  | 3 867 MSEK 2026-03-10 12:02:59 AstraZeneca: Notice of Annual General Meeting 14654,00 SEK | +1,47%  | 5 690 MSEK 2026-03-09 07:35:35 AstraZeneca: Enhertu granted Priority Review in the US as post-neoadjuvant treatment for patients with HER2-positive early breast cancer 14442,00 SEK | -0,40%  | 5 411 MSEK 2026-02-27 08:03:15 AstraZeneca: Strensiq approved for restricted reimbursement in Sweden 15542,00 SEK | +2,86%  | 4 853 MSEK 2026-02-25 08:01:53 AstraZeneca: Filing of Annual Report on Form 20-F with the US Securities and Exchange Commission 15218,00 SEK | -0,70%  | 6 715 MSEK 2026-02-24 12:02:51 AstraZeneca: Annual Financial Report 15326,00 SEK | -0,12%  | 12 622 MSEK Visa fler Enter your email address and you will get a mail for verification you subscription to content on this page and filter Email Prenumerera Det måste ange en riktig mailadress Ett verifikationsmail har skickats till adressen Select the time zone location for site wide time Timezone Europe London Oslo Stockholm Helsinki America New York / Eastern Chicago / Central Los Angeles / Western Change Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto Företag Pressmeddelanden Den här websidan använder cookies för att ge dig den bästa upplevelsen av sidan. Läs mer Acceptera cookies MFN - en produkt från Hemsida Karriär LinkedIn